Fondazione Telethon Ets

5 trials 2 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

0 Completed trials

1 Countries active

14 Unique IMPs

N/A Results reported

Phase III

Phase II

Phase I (FiH)

Phase III: 2 Phase II: 1 Phase I (FiH): 2

Top indications

Hyper IgM syndrome 1 Immunodeficiency 1

Top IMPs

ETUVETIDIGENE AUTOTEMCEL 2 PLERIXAFOR 2 AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING THE HUMAN BETA-GLOBIN GENE 1 AUTOLOGOUS HAEMATOPOIETIC STEM AND PROGENITOR CELL POPULATION CONTAINING CD34+ CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR ENCODING THE TCIRG1 CDNA EX VIVO EXPANDED 1 AUTOLOGOUS PERIPHERAL BLOOD-DERIVED CD4 T-CELLS CRISPR-EDITED AT THE CD40LG LOCUS 1 BUSULFAN 1 LENOGRASTIM 1 PERTUSSIS FILAMENTOUS HAEMAGGLUTININ ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, PERTUSSIS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, TETANUS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, PERTUSSIS PERTACTIN ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, HAEMOPHILUS TYPE B POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID ADSORBED ON ALUMINIUM PHOSPHATE, HEPATITIS B SURFACE ANTIGEN (RDNA) ADSORBED ON ALUMINIUM PHOSPHATE [PRODUCED IN S. CEREVISAE CELLS BY RDNA], DIPHTHERIA TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, POLIOVIRUS (INACTIVATED) TYPE 1 (MAHONEY STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 2 (MEF-1 STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT STRAIN) PRODUCED ON VERO CELLS 1 RABIES VIRUS (INACTIVATED) STRAIN FLURY LEP 1 THIOTEPA 1 TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), NEUDOERFL STRAIN 1 TREOSULFAN 1

All trials

5 total

A phase I/II open label study to assess safety, feasibility and efficacy of ex vivo expanded, autologous haematopoietic stem and progenitor … Pending

2024-518972-30-00 Phase I (FiH) 1 country AUTOLOGOUS HAEMATOPOIETIC STEM AND PROGENITOR CELL POPULATION CONTAINING CD34+ C…
A single arm, open label, multicenter, single-dose, phase 2b clinical study evaluating efficacy and safety of gene therapy using autologous … Pending

2025-522160-32-00 Phase II 1 country AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING THE HUMAN BETA…
An Open Label, Single Arm, Phase I/II Clinical Study of Autologous CD4+ T-Cells Edited Ex-Vivo at the CD40LG Locus by CRISPR/Cas9 and IDLV-b… Pending

2025-524635-39-00 Phase I (FiH) 1 country AUTOLOGOUS PERIPHERAL BLOOD-DERIVED CD4 T-CELLS CRISPR-EDITED AT THE CD40LG LOCU…
A Long-term Follow-up Study for Subjects Previously Treated with Autologous ex vivo Lentiviral Hematopoietic Stem and Progenitor Cell Gene T… Recruiting

2024-518369-92-00 Phase III 1 country ETUVETIDIGENE AUTOTEMCEL
A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects with WAS. Recruiting

2024-517792-20-00 Phase III 1 country ETUVETIDIGENE AUTOTEMCEL

Showing 1–5 of 5 trials

← All sponsors A–Z